Henry Meds vs Ro: Which Telehealth Platform Wins in 2026?
Henry Meds and Ro represent the two ends of the telehealth GLP-1 spectrum: Henry leans into compounded pricing flexibility and a deep ED/TRT formulary; Ro is the household-name brand-name GLP-1 leader with one of the largest insurance-navigation operations in the category.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
Henry Meds and Ro are both broad-category telehealth platforms that prescribe GLP-1 medications, but they differ significantly in clinical model and pricing structure. Henry Meds is a membership-based platform focused on compounded GLP-1s at a flat monthly price, with a strong emphasis on pricing transparency and affordability. Ro is a larger multi-category platform (weight loss, ED, hair, women's health) that offers both compounded and brand-name GLP-1 access, with a more complex pricing structure that varies by medication and dose.
The key differentiator is what you're optimising for. If predictable, low all-in pricing for compounded semaglutide or tirzepatide is the priority, Henry Meds is one of the most transparent options in the market. If you want a single platform that can also handle ED, hair loss, or women's health alongside weight management, Ro's multi-category breadth is a genuine advantage. Neither platform is better in absolute terms — the right choice depends on your specific needs.
Henry Meds
Affordable subscription telehealth with one of the largest compounded formularies in the industry.
Ro
Mainstream telehealth giant with FDA-approved GLP-1s, an insurance concierge, and prepay savings.
Side-by-Side Comparison
| Attribute | Henry Meds | Ro |
|---|---|---|
| Program Fee | Included in monthly plan | $39 first month; then $149/mo, or $74/mo prepaid annually |
| Medication From | From $179 – $297/mo | From $149 – $449/mo |
| Editor Score | 4.6 / 5 | 4.6 / 5 |
| Primary Category | GLP-1 Weight Loss | GLP-1 Weight Loss |
| FDA Brand-Name Access | KYZATREX | Ozempic, Wegovy, Zepbound, Foundayo |
| Compounded Options | 9 compounds | 2 compounds |
| Adjacent Categories | GLP-1 Weight Loss, TRT & Men's Hormones, Women's Health & HRT, Erectile Dysfunction | GLP-1 Weight Loss, Erectile Dysfunction, Hair Loss, Skincare, Primary Care |
What the Studies Actually Show
Pricing reflects publicly listed self-pay rates as of 2026. Insurance acceptance varies by employer plan and pharmacy benefit manager; Ro publishes a coverage tool but cannot guarantee approval. Compounded GLP-1 availability is subject to FDA shortage list status and may change.
| Endpoint | Henry Meds | Ro |
|---|---|---|
| Mean weight loss for the underlying medications (pivotal Phase 3 trials)1,2 | Compounded semaglutide tracks branded semaglutide (Wegovy) at −14.9% over 68 weeks at the 2.4 mg dose Compounded semaglutide has not itself been studied in randomized trials; efficacy is inferred from the active ingredient. The FDA does not formally approve compounded products, so quality depends on the 503A or 503B pharmacy that produces them. | Brand-name Wegovy −14.9%; brand-name Zepbound −20.9% (15 mg) at 72 weeks |
| GI side effects (per FDA prescribing information)3,4 | Same active ingredient profile: nausea, diarrhea, vomiting, constipation in ≥10% of users | Same active ingredient profile: nausea, diarrhea, vomiting, constipation in ≥10% of users |
| Cardiovascular outcomes evidence (semaglutide 2.4 mg)5 | SELECT trial showed 20% MACE risk reduction in adults with established CV disease and overweight/obesity | Same |
Who Should Choose Henry Meds vs Ro
Choose Henry Meds if…
- You're paying cash for compounded semaglutide and want one price that covers visits, medication and shipping.
- You can prepay: Henry's 12-month plan works out to about $197 a month.
- You also want compounded ED or TRT options from the same provider.
Choose Ro if…
- You have, or might get, insurance coverage for Wegovy, Zepbound or Foundayo: Ro's insurance concierge handles prior authorization.
- You want FDA-approved brand-name medication rather than compounded.
- You're fine paying a membership ($74 a month prepaid annually, $149 monthly) on top of medication.
Monthly Cost Compared
| Henry Meds | Ro | |
|---|---|---|
| Membership or program fee | Included in monthly plan | $39 first month; then $149/mo, or $74/mo prepaid annually |
| Published price | From $179 – $297/mo | From $149 – $449/mo |
| All-in at a maintenance dose | $197 to $297/mo compounded semaglutide | $423 to $498/mo wegovy pen (est.); $523 to $598/mo zepbound (est.) |
| Public reviews (Trustpilot) | 4.4/5 from 12,520 | 3.9/5 from 6,102 |
| Prices last checked | 21 October 2026 | 21 October 2026 |
Prices come from each provider's own pages on the dates shown and change often; maintenance figures include any required membership. Compare every provider in the GLP-1 price tracker.
The Verdict
Choose Henry Meds for compounded GLP-1 access at lower out-of-pocket cost and the deepest ED/TRT formulary. Choose Ro if insurance coverage for FDA-approved Wegovy or Zepbound is a priority, or if you value the breadth of conditions a single platform can manage.
Frequently Asked Questions
Is Henry Meds or Ro cheaper for GLP-1?
Henry Meds is cheaper out-of-pocket for compounded GLP-1 (typically $250–$350/mo). Ro's compounded GLP-1 program is similarly priced, but Ro's main pricing advantage is for patients with insurance coverage of brand-name Wegovy or Zepbound, where copays can drop to $25–$50/mo. For uninsured patients, Henry Meds is generally cheaper; for insured patients with weight-loss coverage, Ro often wins.
Which platform has better insurance navigation?
Ro, by a wide margin. Ro operates one of the largest insurance-navigation operations in the telehealth weight-loss category, with dedicated coverage tools, prior-auth handling, and partnerships with major PBMs. Henry Meds operates almost exclusively cash-pay and does not file insurance claims. If your insurance covers Wegovy or Zepbound, Ro is the platform that will actually help you access that coverage.
Can I get brand-name Wegovy or Zepbound at Henry Meds?
As of 2026, Henry Meds focuses on compounded semaglutide and tirzepatide rather than brand-name products. Patients who want FDA-approved Wegovy or Zepbound through telehealth should use Ro, Eden, or NovoCare/LillyDirect directly. Henry Meds adds value primarily for patients who want compounded pricing and same-platform access to ED, TRT, and other men's-health prescriptions.
Which platform has more clinical oversight?
Both platforms employ licensed prescribers and require an intake questionnaire plus virtual consultation. Ro has a larger clinical team, structured protocols, and ongoing nurse messaging. Henry Meds is leaner but uses board-certified physicians and has not been associated with the quality concerns that have plagued some lower-cost compounded GLP-1 platforms. Both are above the floor for telehealth clinical practice.
Does Ro require lab work for GLP-1?
Ro requires baseline metrics (height, weight, BMI calculation) and a virtual consultation but does not universally require pre-treatment labs for GLP-1. Some patients with relevant medical history (diabetes, thyroid disease, family history of MTC) are required to provide labs. Henry Meds has a similar policy. Patients with no concerning history can typically start GLP-1 without lab work at either platform, which is consistent with most telehealth GLP-1 programs but below the standard of in-person endocrinology care.
Which platform should I choose for ED or TRT?
Henry Meds, it has a deeper men's-health formulary including TRT, sildenafil, tadalafil, and finasteride alongside GLP-1. Ro also offers ED and hair loss but has wound down its TRT program in favor of focusing on GLP-1. For patients who want a single platform handling weight loss + ED/TRT, Henry Meds is the cleaner choice.
- STEP 1 Trial. NEJM 2021 · Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989–1002.
- SURMOUNT-1 Trial. NEJM 2022 · Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205–216.
- SELECT Trial. NEJM 2023 · Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221–2232.
RxNotebook is an editorial publication, not a medical practice. We are not affiliated with the cited studies; source material does not endorse the providers shown. This is general information, not medical advice.